Edwards Lifesciences (NYSE:EW) Price Target Lowered to $73.00 at Evercore ISI

Edwards Lifesciences (NYSE:EW) had its price target cut by research analysts at Evercore ISI from $75.00 to $73.00 in a research report issued on Wednesday,Benzinga reports. The firm currently has an “in-line” rating on the medical research company’s stock. Evercore ISI’s price target indicates a potential upside of 2.89% from the stock’s previous close.

EW has been the subject of a number of other reports. JPMorgan Chase & Co. boosted their target price on shares of Edwards Lifesciences from $72.00 to $78.00 and gave the company a “neutral” rating in a research note on Friday, October 25th. The Goldman Sachs Group increased their target price on Edwards Lifesciences from $81.00 to $90.00 and gave the company a “buy” rating in a report on Thursday, December 5th. Sanford C. Bernstein upgraded Edwards Lifesciences from a “strong sell” rating to a “hold” rating in a research note on Monday, October 28th. Piper Sandler lowered their price objective on shares of Edwards Lifesciences from $73.00 to $70.00 and set a “neutral” rating on the stock in a research note on Friday, October 25th. Finally, Truist Financial restated a “hold” rating and set a $78.00 target price (up from $70.00) on shares of Edwards Lifesciences in a research report on Thursday, December 5th. One research analyst has rated the stock with a sell rating, fourteen have assigned a hold rating and twelve have given a buy rating to the stock. According to data from MarketBeat.com, the stock has a consensus rating of “Hold” and an average price target of $79.57.

Edwards Lifesciences Trading Down 0.2 %

Shares of NYSE EW opened at $70.95 on Wednesday. The company has a market cap of $41.85 billion, a PE ratio of 10.24, a P/E/G ratio of 3.64 and a beta of 1.10. The company has a debt-to-equity ratio of 0.06, a quick ratio of 2.89 and a current ratio of 3.46. The firm’s 50 day moving average price is $72.47 and its 200-day moving average price is $69.32. Edwards Lifesciences has a 52-week low of $58.93 and a 52-week high of $96.12.

Edwards Lifesciences (NYSE:EW) last posted its earnings results on Tuesday, February 11th. The medical research company reported $0.59 earnings per share (EPS) for the quarter, beating the consensus estimate of $0.55 by $0.04. Edwards Lifesciences had a net margin of 70.82% and a return on equity of 20.76%. On average, equities research analysts expect that Edwards Lifesciences will post 2.56 EPS for the current fiscal year.

Insider Buying and Selling at Edwards Lifesciences

In other news, VP Daniel J. Lippis sold 500 shares of the stock in a transaction that occurred on Thursday, January 16th. The stock was sold at an average price of $68.76, for a total value of $34,380.00. Following the sale, the vice president now directly owns 23,189 shares in the company, valued at approximately $1,594,475.64. This represents a 2.11 % decrease in their ownership of the stock. The sale was disclosed in a filing with the SEC, which can be accessed through the SEC website. Company insiders own 1.29% of the company’s stock.

Institutional Trading of Edwards Lifesciences

A number of hedge funds and other institutional investors have recently bought and sold shares of the business. Crowley Wealth Management Inc. bought a new stake in shares of Edwards Lifesciences during the fourth quarter valued at approximately $26,000. Millstone Evans Group LLC bought a new position in shares of Edwards Lifesciences during the fourth quarter valued at approximately $29,000. Migdal Insurance & Financial Holdings Ltd. bought a new position in shares of Edwards Lifesciences in the 4th quarter worth $30,000. FSA Wealth Management LLC acquired a new position in shares of Edwards Lifesciences during the third quarter worth $30,000. Finally, Prospera Private Wealth LLC purchased a new position in Edwards Lifesciences during the 3rd quarter worth $32,000. Hedge funds and other institutional investors own 79.46% of the company’s stock.

About Edwards Lifesciences

Edwards Lifesciences Corporation provides products and technologies for structural heart disease and critical care monitoring in the United States, Europe, Japan, and internationally. It offers transcatheter heart valve replacement products for the minimally invasive replacement of aortic heart valves under the Edwards SAPIEN family of valves system; and transcatheter heart valve repair and replacement products to treat mitral and tricuspid valve diseases under the PASCAL PRECISION and Cardioband names.